ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
만성폐쇄성폐질환(COPD) 치료 시장 규모는 2025년 293억 1,000만 달러에서 2026-2034년에 CAGR 5.02%로 성장하며, 2034년에는 455억 5,000만 달러에 달할 것으로 예측되고 있습니다.
만성폐쇄성폐질환(COPD) 치료제 시장은 전 세계에서 COPD 유병률이 지속적으로 증가함에 따라 큰 폭의 성장이 예상됩니다. COPD는 진행성 폐질환으로 기류 제한이 특징이며, 호흡곤란과 삶의 질 저하를 초래하는 질환입니다. 흡연, 대기오염, 직업적 노출과 같은 위험요인 증가는 기관지확장제, 코르티코스테로이드, 병용요법 등 효과적인 COPD 치료제에 대한 수요를 촉진하고 있습니다. 의료진들이 환자의 예후 개선과 증상 관리를 추구함에 따라 COPD 치료제 시장은 확대될 것으로 예측됩니다.
기술 혁신은 COPD 치료 시장 전망를 형성하는 데 중요한 역할을 하고 있습니다. 흡입기, 분무기 등 약물전달 시스템의 혁신으로 COPD 치료의 효과와 편의성이 향상되고 있습니다. 또한 모바일 애플리케이션과 원격 모니터링 기기를 포함한 디지털 헬스 기술을 통합하여 환자가 자신의 상태를 보다 효과적으로 관리할 수 있도록 돕고 있습니다. 제조업체들이 연구개발에 대한 투자를 지속하는 가운데 COPD 치료제 시장은 다양한 헬스케어 현장에서 혁신적인 솔루션의 도입이 확대될 것으로 예측됩니다.
또한 환자 교육과 자가 관리에 대한 관심이 높아지는 것도 COPD 치료 시장의 성장 궤도에 영향을 미치고 있습니다. 환자들이 자신의 질환과 치료 옵션에 대한 이해도가 높아짐에 따라 효과적인 자가 관리를 돕는 자원과 지원 시스템에 대한 수요가 증가하고 있습니다. 이러한 추세에 따라 의료 프로바이더, 제약사, 환자 지원 단체가 협력하여 환자가 자신의 헬스케어를 주도할 수 있도록 돕는 교육 프로그램을 개발하고 있습니다. 시장이 계속 진화하는 가운데, 기술 통합, 환자와의 관계, 개인화된 치료가 성공의 중요한 원동력이 될 것입니다.
목차
제1장 서론
제2장 개요
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 만성폐쇄성폐질환(COPD) 치료 시장 : 약제 클래스별
제5장 세계의 만성폐쇄성폐질환(COPD) 치료 시장 : 유형별
제6장 세계의 만성폐쇄성폐질환(COPD) 치료 시장 : 유통 채널별
제7장 세계의 만성폐쇄성폐질환(COPD) 치료 시장 : 지역별
제8장 경쟁 구도
제9장 기업 개요
KSA
영문 목차
영문목차
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size is expected to reach USD 45.55 Billion in 2034 from USD 29.31 Billion (2025) growing at a CAGR of 5.02% during 2026-2034.
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is poised for significant growth as the prevalence of COPD continues to rise globally. COPD is a progressive lung disease characterized by airflow limitation, leading to breathing difficulties and reduced quality of life. The increasing incidence of risk factors such as smoking, air pollution, and occupational exposures is driving the demand for effective COPD treatments, including bronchodilators, corticosteroids, and combination therapies. As healthcare providers seek to improve patient outcomes and manage symptoms, the market for COPD treatments is expected to flourish.
Technological advancements are playing a crucial role in shaping the future of the COPD treatment market. Innovations in drug delivery systems, such as inhalers and nebulizers, are enhancing the efficacy and convenience of COPD therapies. Additionally, the integration of digital health technologies, including mobile applications and remote monitoring devices, is empowering patients to manage their condition more effectively. As manufacturers continue to invest in research and development, the COPD treatment market is likely to see increased adoption of innovative solutions across various healthcare settings.
Moreover, the growing emphasis on patient education and self-management is influencing the COPD treatment market's growth trajectory. As patients become more informed about their condition and treatment options, there is a rising demand for resources and support systems that facilitate effective self-management. This trend is driving collaboration between healthcare providers, pharmaceutical companies, and patient advocacy groups to develop educational initiatives that empower patients to take control of their health. As the market continues to evolve, the integration of technology, patient engagement, and personalized care will be key drivers of success.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Drug Class
Combination Therapy
Bronchodilators
Corticosteroids
Phosphodiesterase Type 4 Inhibitor
Mucokinetics
Others
By Type
Chronic Bronchitis
Emphysema
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
COMPANIES PROFILED
Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici Sp A, F HoffmannLa Roche Ltd, GlaxoSmithKiine plc, Kyowa Hakko Kirin, Mylan NV, Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd, Teva Pharmaceutical Industries Ltd, Theravance Biopharma, Verona Pharmaceuticals
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1 Information Analysis
1.3.2 Market Formulation & Data Visualization
1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
3.4.1 Standards & Compliance
3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
3.5.1 Market Drivers
3.5.2 Market Restraints
3.5.3 Market Opportunities
3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)
4.1. Market Analysis, Insights and Forecast Drug Class
4.2. Combination Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Bronchodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Phosphodiesterase Type 4 Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Mucokinetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)
5.1. Market Analysis, Insights and Forecast Type
5.2. Chronic Bronchitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Emphysema Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
6.1. Market Analysis, Insights and Forecast Distribution Channel
6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY REGION 2022-2034(USD MN)
7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.2.1 By Drug Class
7.2.2 By Type
7.2.3 By Distribution Channel
7.2.4 United States
7.2.5 Canada
7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.3.1 By Drug Class
7.3.2 By Type
7.3.3 By Distribution Channel
7.3.4 United Kingdom
7.3.5 France
7.3.6 Germany
7.3.7 Italy
7.3.8 Russia
7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.4.1 By Drug Class
7.4.2 By Type
7.4.3 By Distribution Channel
7.4.4 India
7.4.5 Japan
7.4.6 South Korea
7.4.7 Australia
7.4.8 South East Asia
7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.5.1 By Drug Class
7.5.2 By Type
7.5.3 By Distribution Channel
7.5.4 Brazil
7.5.5 Argentina
7.5.6 Peru
7.5.7 Chile
7.5.8 South East Asia
7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.6.1 By Drug Class
7.6.2 By Type
7.6.3 By Distribution Channel
7.6.4 Saudi Arabia
7.6.5 UAE
7.6.6 Israel
7.6.7 South Africa
7.6.8 Rest of the Middle East And Africa
Chapter 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping
Chapter 9. COMPANY PROFILES OF GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY
9.1. Top Companies Market Share Analysis
9.2. Company Profiles
9.2.1 Almirall
9.2.2 AstraZeneca
9.2.3 Boehringer Ingelheim International GmbH
9.2.4 CHIESI Farmaceutici S.P A
9.2.5 F. Hoffmann-La Roche Ltd
9.2.6 GlaxoSmithKiine Plc
9.2.7 Kyowa Hakko Kirin
9.2.8 Mylan NV
9.2.9 Novartis AG
9.2.10 Orion Corporation
9.2.11 Sanofi
9.2.12 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd)
